Mapping the Certolizumab Pegol Epitope on Tumor Necrosis Factor and Comparison With Infliximab, Adalimumab, and Etanercept

被引：0
|
作者：
Henry, Alistair
Gong, Hai Ping
Nesbitt, Andrew N.
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S630 / S630
页数：1
相关论文
共 50 条
  • [41] Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations
    van Bezooijen, Ji S.
    Koch, Birgit C. P.
    van Doorn, Martijn B. A.
    Prens, Errol P.
    van Gelder, Teun
    Schreurs, Marco W. J.
    THERAPEUTIC DRUG MONITORING, 2016, 38 (04) : 432 - 438
  • [42] Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept?
    Ehlers, S
    CLINICAL INFECTIOUS DISEASES, 2005, 41 : S199 - S203
  • [43] Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
    Lee, JH
    Slifman, NR
    Gershon, SK
    Edwards, ET
    Schwieterman, WD
    Siegel, JN
    Wise, RP
    Brown, SL
    Udall, JN
    Braun, MM
    ARTHRITIS AND RHEUMATISM, 2002, 46 (10): : 2565 - 2570
  • [44] Killing of cells expressing membrane TNF by Complement-Dependent cytotoxicity and antibody-dependent cellular cytotoxicity: In vitro comparison of the anti-TNF agents certolizumab pegol, adalimumab, etanercept, and infliximab.
    Fossati, Gianluca
    Nesbitt, Andrew
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S599 - S599
  • [45] In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870)
    Fossati, G
    Nesbitt, AM
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S299 - S299
  • [46] Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
    Victoria Hernandez, M.
    Mesquida, Marina
    Llorens, Victor
    Sainz de la Maza, Maite
    Espinosa, Gerard
    Blanco, Ricardo
    Calvo, Vanesa
    Maiz, Olga
    Blanco, Ana
    Ramon De Dios, Juan
    Ahijado-Guzman, Pilar
    Judez, Enrique
    Tejon, Patricia
    Soledad Pena, M.
    Sanmarti, Raimon
    Adan, Alfredo
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [47] CERTOLIZUMAB PEGOL INHIBITS TUMOUR NECROSIS FACTOR-INDUCED ENDOTHELIAL CELL ACTIVATION
    Heathfield, S. K.
    Bruce, I.
    Alexander, M. Y.
    HEART, 2011, 97 (20) : 5 - 6
  • [48] Placental transfer in rats of IGG1 and pegylated FAB 'versions of the anti-TNF agent TN3: Potential implications for adalimumab, etanercept, infliximab and certolizumab pegol
    Stephens, S.
    Nesbitt, A. M.
    Foulkes, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 502 - 502
  • [49] Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
    Skov, Lone
    Kragballe, Knud
    Dam, Tomas
    Poulsen, Johan Holk
    Obitz, Erik
    Gniadecki, Robert
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S61 - S61
  • [50] Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
    Hebeisen, Monika
    Scherer, Almut
    Micheroli, Raphael
    Nissen, Michael J.
    Tamborrini, Giorgio
    Moller, Burkhard
    Zufferey, Pascal
    Exer, Pascale
    Ciurea, Adrian
    PLOS ONE, 2019, 14 (05):
12345